KRAS and colorectal cancer: The epidermal growth factor receptor (EGFR) is a major therapeutic target in colorectal cancers, and the KRAS mutation test is essential in clinical practice for predicting resistance to EGFR inhibitors during metastatic colorectal cancer treatment [14–16].